Potassium channels as therapeutic targets for autoimmune disorders.

Christine Beeton, K George Chandy, Heike Wulff

Journal: Current opinion in drug discovery & development 2003;6(5):640-7

PMID: 14579513

Abstract

In human T-lymphocytes, the voltage-gated Kv1.3 channel and the Ca(2+)-activated IKCa1 channel play an important role in Ca2+ signaling, activation, adhesion and migration and have, therefore, long been regarded as attractive targets for immunotherapy. Here, we review the pharmacology of the two channels, their expression pattern in naïve and memory T-cells and their functional roles during T-cell activation, and explain the rationale for the use of Kv1.3 blockers for the therapy of T-cell mediated autoimmune diseases.

Address: University of California, Davis Department of Pharmacology and Toxicology, School of Medicine, Tupper Hall, One Shields Avenue, Davis, CA 95616, USA.

Link outs

Free resources

Medical:

https://medlineplus.gov/multiplesclerosis.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Miscellaneous:

https://assays.cancer.gov/CPTAC-177

MeSH Terms: Humans, Intermediate-Conductance Calcium-Activated Potassium Channels, Kv1.3 Potassium Channel, Lymphocyte Activation, Multiple Sclerosis, Phenotype, Potassium Channel Blockers, Potassium Channels, Potassium Channels, Voltage-Gated, T-Lymphocytes